Soleno

Soleno has developed a once-daily oral tablet, diazoxide choline, for the treatment of Prader-Willi Syndrome and which achieved FDA approval in March 2025. Previously, no therapies were approved to treat this rare genetic condition, which causes chronic insatiable hunger as well as behavioural problems, cognitive disabilities, low muscle tone and short stature. The product has orphan drug designation in the US and Europe. Soleno is a VIPE (Venture Investment in Public Equity) and is listed on Nasdaq with the ticker SLNO.